Maze Therapeutics Appoints Misbah Tahir as Chief Financial Officer

SOUTH SAN FRANCISCO, Calif., Sept. 02, 2025 (GLOBE NEWSWIRE) -- Maze Therapeutics, Inc. (NASDAQ:MAZE), a clinical-stage biopharmaceutical company developing small molecule precision medicines for patients with kidney and metabolic diseases, today announced the appointment of Misbah Tahir as chief financial officer (CFO), effective immediately.

"We're thrilled to welcome Misbah as Maze's Chief Financial Officer at such a pivotal time for the company. We are preparing for several key milestones, including data for MZE782 in phenylketonuria and chronic kidney disease in Q3 2025 and initial data from our Phase 2 HORIZON trial of MZE829 in APOL1-mediated kidney disease in Q1 2026," said Jason Coloma, Ph.D., chief executive officer of Maze. "Misbah's proven track record in scaling biotech companies, combined with deep financial and operational expertise, will be instrumental in driving our growth strategy as we maintain our focus on clinical execution."

Mr. Tahir brings more than 20 years of financial and strategic experience in the biopharmaceutical industry. He most recently served as CFO of IGM Biosciences, Inc., where he helped lead the company's 2019 initial public offering and worked with the executive team to raise more than $1 billion across multiple equity financings and a pharma partnership. Previously, he held senior finance positions at Dermira, Inc. (acquired by Eli Lilly and Company), Onyx Pharmaceuticals, Inc. (acquired by Amgen Inc.), and Human Genome Sciences Inc. (acquired by GSK plc) where he played key roles in capital formation, pharma collaboration, and product launches. Mr. Tahir began his industry career at Amgen, Inc. after working as a management consultant at the consulting firm of Oliver Wyman. He holds an M.B.A. from the University of Michigan Business School and a B.A. in International Relations from the University of Pennsylvania.

"Maze's strong balance sheet and expected cash runway into 2H 2027, combined with its differentiated precision genetics platform, advancing clinical pipeline, and disciplined development approach have given the company the opportunity to create significant value for both patients and shareholders," said Mr. Tahir. "I look forward to partnering with Jason and the entire leadership team to drive the next phase for Maze as we work together to harness the power of human genetics to develop potentially novel, small molecule precision medicines for patients with kidney and metabolic diseases."

About Maze Therapeutics

Maze Therapeutics is a clinical-stage biopharmaceutical company harnessing the power of human genetics to develop novel, small molecule precision medicines for patients with kidney and metabolic diseases. Guided by its Compass platform, Maze pursues genetically validated targets by integrating variant discovery and functionalization to discover and advance oral small molecule programs with first- or best-in-class potential. Maze's pipeline is led by MZE829, an oral APOL1 inhibitor in Phase 2 development for APOL1-mediated kidney disease, and MZE782, an oral SLC6A19 inhibitor advancing through Phase 1 with the potential to treat both chronic kidney disease (CKD) and phenylketonuria (PKU). Maze is headquartered in South San Francisco. For more information, please visit mazetx.com, or follow the company on LinkedIn and X.

Forward Looking Statements

This press release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements reflect the current beliefs and expectations of management. All statements other than statements of historical fact are statements that could be deemed forward-looking statements, including, without limitation, statements concerning the company's future plans and prospects, any expectations regarding the safety or efficacy of MZE829, MZE782 and other candidates under development, the ability of MZE829 to treat AMKD or other indications, the ability of MZE782 to treat CKD, PKU or other indications, the planned timing of the company's clinical trials, data results and further development of MZE829, MZE782 and other therapeutic candidates, and the ability to drive financial results and stockholder value. In addition, when or if used in this press release, the words "may," "could," "should," "anticipate," "believe," "estimate," "expect," "intend," "plan," "predict" and similar expressions and their variants, as they relate to the company may identify forward-looking statements. Forward-looking statements are neither historical facts nor assurances of future performance. Although the company believes the expectations reflected in such forward-looking statements are reasonable, the company can give no assurance that such expectations will prove to be correct. Readers are cautioned that actual results, levels of activity, safety, performance or events and circumstances could differ materially from those expressed or implied in the company's forward-looking statements due to a variety of factors, including risks and uncertainties related to the company's ability to advance MZE829, MZE782 and its other therapeutic candidates, obtain regulatory approval of and ultimately commercialize the company's therapeutic candidates, the timing and results of preclinical studies and clinical trials, the company's ability to fund development activities and achieve development goals, its ability to protect its intellectual property, general business and economic conditions, and risks related to the impact on its business of macroeconomic conditions, including inflation, volatile interest rates, tariffs, instability in the global banking sector, and public health crises. Further information on potential risk factors that could affect the company's business and its financial results are detailed under the heading "Risk Factors" included in the documents the company files from time to time with the U.S. Securities and Exchange Commission, including the company's Annual Report on Form 10-K and Quarterly Reports on Form 10-Q. Accordingly, readers are cautioned not to place undue reliance on these forward-looking statements. These forward-looking statements speak only as of the date of this press release and the company undertakes no obligation to revise or update any forward-looking statements to reflect events or circumstances after the date hereof.

IR/Corporate Contact:

Amy Bachrodt, Maze Therapeutics

[email protected]

Media Contact:

Amanda Lazaro, 1AB Media

[email protected]